Tag Archives: Mallinckrodt

The EVP & Chief Comm & Ops Ofcr of Mallinckrodt (Other OTC: MNKKQ) is Selling Shares

Today, the EVP & Chief Comm & Ops Ofcr of Mallinckrodt (MNKKQ – Research Report), Hugh O’neill, sold shares of MNKKQ for $525. In addition to Hugh O’neill, one other MNKKQ executive reported Sell trades in the last month. See

The EVP & Chief Comm & Ops Ofcr of Mallinckrodt (Other OTC: MNKKQ) is Selling Shares

On November 18, the EVP & Chief Comm & Ops Ofcr of Mallinckrodt (MNKKQ – Research Report), Hugh O’neill, sold shares of MNKKQ for $90. This is O’neill’s first Sell trade following 3 Buy transactions. In addition to Hugh O’neill,

A Director at Mallinckrodt (Other OTC: MNKKQ) is Selling Shares

Yesterday, a Director at Mallinckrodt (MNKKQ – Research Report), Angus Russell, sold shares of MNKKQ for $6,214. This is Russell’s first transaction since reporting a Buy transaction on TXMD back in August 2019 In addition to Angus Russell, one other

Mallinckrodt (MNK) Gets a Hold Rating from Raymond James

Raymond James analyst Elliot Wilbur reiterated a Hold rating on Mallinckrodt (MNK – Research Report) yesterday. The company’s shares closed last Monday at $1.10, close to its 52-week low of $1.00. According to TipRanks.com, Wilbur has currently 0 stars on

Analysts Conflicted on These Healthcare Names: Mallinckrodt (NYSE: MNK), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cocrystal Pharma (NASDAQ: COCP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mallinckrodt (MNK – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and Cocrystal Pharma (COCP – Research Report). Mallinckrodt (MNK) In a report released yesterday,

Mallinckrodt (MNK) Gets a Sell Rating from Merrill Lynch

In a report released today, Jason Gerberry from Merrill Lynch maintained a Sell rating on Mallinckrodt (MNK – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $4.18, close to its 52-week low of